PEDIATRIC INTERVENTIONAL CARDIOLOGY MARKET ANALYSIS

Pediatric Interventional Cardiology MarketBy Device Type (Transcatheter Heart Valves, Closure Devices, Catheters, Guidewires, Balloons, Stents, and Others), By Procedure (Angioplasty, Coronary Thrombectomy, Congenital Heart Defect Correction, Catheter-based Valve Implantation, and Others), By End User (Hospitals, Ambulatory Surgical Centers, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On September 11, 2024, Children’s Hospital Los Angeles (CHLA) achieved a significant milestone in pediatric cardiology with the introduction of the Minima stent. This innovative cardiac stent is specifically designed for infants and young children and can be expanded to adult sizes as the child grows.
On September 8, 2024, Children’s National Hospital, in collaboration with Additional Ventures, a nonprofit foundation, announced grants worth US$ 300,000 aimed at promoting innovation in pediatric cardiology devices. This initiative is part of the Alliance for Pediatric Device Innovation (APDI), a non-profit consortium dedicated to developing medical technologies specifically tailored for children with heart conditions.
On August 29, 2024, Renata Medical, a healthcare technology firm based in U.S., received approval from the U.S. Food and Drug Administration (FDA) for a new stent specifically designed for pediatric patients with congenital heart defects. This innovative device aims to address the unique needs of neonates, infants, and young children.
On May 16, 2024, Atraverse Medical, a U.S.-based medical device company, received the U.S. Food and Drug Administration approval for its Hotwire guidewire